Source:http://linkedlifedata.com/resource/pubmed/id/11775180
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2001-12-31
|
pubmed:abstractText |
Knowledge of lymphatic involvement in patients with colorectal cancer is important in surgery and in the postoperative decision-making process. Fifty-eight patients with recurrent colorectal cancer underwent operation with the RIGS/(Radioimmunoguided Surgery) technology. Preoperatively, patients were injected with 1 mg monoclonal antibody (MoAb) CC49 (anti-TAG-72-tumor-associated glycoprotein) labeled with 2 mCi of iodine 125. Traditional surgical exploration was followed by survey with a gamma-detecting probe. Localization of MoAb on tumor was noted in 54/58 patients (93%). Traditional exploration identified 117 suspected tumor sites. With RIGS, 177 suspected tumor sites were detected. In 17 of the 58 patients (27.5%), at least one occult tumor site identified by RIGS was confirmed by pathology with hematoxylin & eosin (H & E) staining. This finding resulted in 16 major changes in surgical plan. RIGS performance varied between lymphatic and non-lymphatic tissue, with a positive predictive value (PPV) of 95.6% and negative predictive value (NPV) of 90% in non-lymphoid tissue compared to PPV of 40% and NPV of 100% in lymphoid tissue. In patients with tumors that localize, no RIGS activity in lymph nodes signifies no tumor, while decisions based on RIGS activity in lymph nodes requires H & E confirmation. Using this guideline, additional information acquired by RIGS can help the surgeon in making an informed decision during surgery and in planning postoperative therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0364-2313
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1495-8; discussion 1499
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11775180-Antibodies, Monoclonal,
pubmed-meshheading:11775180-Antibodies, Neoplasm,
pubmed-meshheading:11775180-Clinical Trials, Phase III as Topic,
pubmed-meshheading:11775180-Colorectal Neoplasms,
pubmed-meshheading:11775180-Humans,
pubmed-meshheading:11775180-Intraoperative Period,
pubmed-meshheading:11775180-Iodine Radioisotopes,
pubmed-meshheading:11775180-Lymph Node Excision,
pubmed-meshheading:11775180-Lymphatic Metastasis,
pubmed-meshheading:11775180-Multicenter Studies as Topic,
pubmed-meshheading:11775180-Neoplasm Recurrence, Local,
pubmed-meshheading:11775180-Predictive Value of Tests,
pubmed-meshheading:11775180-Radioimmunodetection,
pubmed-meshheading:11775180-Tomography, X-Ray Computed
|
pubmed:year |
2001
|
pubmed:articleTitle |
Immunoguided lymph node dissection in colorectal cancer: a new challenge?
|
pubmed:affiliation |
Radioguided Surgery Unit, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv Sourasky Medical Center, Israel. rgssch@tasmc.health.gov.il
|
pubmed:publicationType |
Journal Article
|